Willmore E - Search Results

1

Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases.

Jobson AG, Willmore E, Tilby MJ, Mistry P, Charlton P, Austin CA. Jobson AG, et al. Among authors: willmore e. Cancer Chemother Pharmacol. 2009 Apr;63(5):889-901. doi: 10.1007/s00280-008-0812-9. Epub 2008 Aug 5. Cancer Chemother Pharmacol. 2009. PMID: 18679685

2

Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells.

Willmore E, Errington F, Tilby MJ, Austin CA. Willmore E, et al. Biochem Pharmacol. 2002 May 15;63(10):1807-15. doi: 10.1016/s0006-2952(02)00920-6. Biochem Pharmacol. 2002. PMID: 12034365

3

Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.

Errington F, Willmore E, Leontiou C, Tilby MJ, Austin CA. Errington F, et al. Among authors: willmore e. Cancer Chemother Pharmacol. 2004 Feb;53(2):155-62. doi: 10.1007/s00280-003-0701-1. Epub 2003 Sep 23. Cancer Chemother Pharmacol. 2004. PMID: 14504921

4

Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.

López-Lázaro M, Willmore E, Jobson A, Gilroy KL, Curtis H, Padget K, Austin CA. López-Lázaro M, et al. Among authors: willmore e. J Nat Prod. 2007 Dec;70(12):1884-8. doi: 10.1021/np070332i. Epub 2007 Dec 13. J Nat Prod. 2007. PMID: 18076140

5

Selenite induces topoisomerase I and II-DNA complexes in K562 leukemia cells.

López-Lázaro M, Willmore E, Elliott SL, Austin CA. López-Lázaro M, et al. Among authors: willmore e. Int J Cancer. 2008 Nov 1;123(9):2217-21. doi: 10.1002/ijc.23783. Int J Cancer. 2008. PMID: 18712718

6

The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells.

López-Lázaro M, Willmore E, Austin CA. López-Lázaro M, et al. Among authors: willmore e. Mutat Res. 2010 Feb;696(1):41-7. doi: 10.1016/j.mrgentox.2009.12.010. Epub 2009 Dec 16. Mutat Res. 2010. PMID: 20025993

7

Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique.

Willmore E, Frank AJ, Padget K, Tilby MJ, Austin CA. Willmore E, et al. Mol Pharmacol. 1998 Jul;54(1):78-85. doi: 10.1124/mol.54.1.78. Mol Pharmacol. 1998. PMID: 9658192

8

Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.

Errington F, Willmore E, Tilby MJ, Li L, Li G, Li W, Baguley BC, Austin CA. Errington F, et al. Among authors: willmore e. Mol Pharmacol. 1999 Dec;56(6):1309-16. doi: 10.1124/mol.56.6.1309. Mol Pharmacol. 1999. PMID: 10570059

9

A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.

Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA, Durkacz BW. Willmore E, et al. Blood. 2004 Jun 15;103(12):4659-65. doi: 10.1182/blood-2003-07-2527. Epub 2004 Mar 9. Blood. 2004. PMID: 15010369 Free article.

10

The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.

Smith LM, Willmore E, Austin CA, Curtin NJ. Smith LM, et al. Among authors: willmore e. Clin Cancer Res. 2005 Dec 1;11(23):8449-57. doi: 10.1158/1078-0432.CCR-05-1224. Clin Cancer Res. 2005. PMID: 16322308

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

61 results

Search Page

Filters